ATHA - Athira Pharma Inc Stock Price, Fair Value and News

2.46USD-0.25 (-9.23%)Market Closed

Market Summary

USD2.46-0.25

Market Closed

-9.23%

ATHA Stock Price

View Fullscreen

ATHA RSI Chart

ATHA Valuation

Market Cap

103.9M

Price/Earnings (Trailing)

-0.89

Price/Sales (Trailing)

16.34

Price/Free Cashflow

-1.03

ATHA Price/Sales (Trailing)

ATHA Profitability

Return on Equity

-108.82%

Return on Assets

-87.03%

Free Cashflow Yield

-96.69%

ATHA Fundamentals

ATHA Revenue

Revenue (TTM)

5.2M

ATHA Earnings

Earnings (TTM)

-116.2M

Earnings Growth (Yr)

5.46%

Earnings Growth (Qtr)

3.61%

Breaking Down ATHA Revenue

52 Week Range

1.783.73

(Low)(High)

Last 7 days

22.1%

Last 30 days

28.4%

Last 90 days

-24.3%

Trailing 12 Months

-1.8%

How does ATHA drawdown profile look like?

ATHA Financial Health

Current Ratio

5.03

ATHA Investor Care

Shares Dilution (1Y)

1.00%

Diluted EPS (TTM)

-3.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	9.2M	7.9M	6.5M	5.2M
2021	3.2M	5.1M	7.0M	8.8M
2020	1.0M	0	0	1.3M
2019	0	0	0	754.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Athira Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 05, 2024	worthington mark	sold	-7,018	2.91	-2,412	general counsel
Jan 05, 2024	litton mark james	sold	-14,026	2.91	-4,820	chief executive officer
Jan 05, 2024	lenington rachel	sold	-7,018	2.91	-2,412	coo and cdo
Jan 05, 2024	litton mark james	sold	-14,026	2.91	-4,820	ceo
Jan 05, 2024	lenington rachel	sold	-7,018	2.91	-2,412	chief operating officer
Jan 05, 2024	church kevin	sold	-7,018	2.91	-2,412	chief scientific officer
Jan 05, 2024	worthington mark	sold	-7,018	2.91	-2,412	general counsel
Jan 05, 2024	gengos andrew	sold	-3,515	2.91	-1,208	cfo and chief business officer
Jan 04, 2024	lenington rachel	acquired	-	-	10,000	coo and cdo
Jan 04, 2024	worthington mark	acquired	-	-	10,000	general counsel

Which funds bought or sold ATHA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	TWO SIGMA ADVISERS, LP	added	23.74	286,832	1,012,430	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	109,740	109,740	-%
May 15, 2024	Royal Bank of Canada	reduced	-77.33	-64,000	22,000	-%
May 15, 2024	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	new	-	22,742	22,742	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-17.02	-33,171	482,166	0.01%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	39.97	427,265	1,166,160	-%
May 15, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	1,674,920	14,804,100	0.26%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-26.03	-464,658	2,336,440	0.24%
May 15, 2024	ALGERT GLOBAL LLC	new	-	40,000	40,000	-%
May 15, 2024	BAKER BROS. ADVISORS LP	unchanged	-	977,680	8,641,430	0.11%

Are Funds Buying or Selling ATHA?

Are funds buying ATHA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATHA

No. of Funds

Unveiling Athira Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	baker bros. advisors lp	8.3%	3,153,807	SC 13G
Dec 29, 2023	perceptive advisors llc	14.2%	5,402,964	SC 13D/A
Jul 07, 2023	blackrock inc.	1.8%	669,768	SC 13G/A
Apr 20, 2023	kayne richard a	5.3%	1,983,668	SC 13G
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 01, 2023	blackrock inc.	6.2%	2,363,221	SC 13G/A
Jan 30, 2023	franklin resources inc	0.0%	0	SC 13G/A
Jul 01, 2022	perceptive advisors llc	12.8%	4,811,149	SC 13D/A
Feb 14, 2022	rtw investments, lp	5.1%	1,906,557	SC 13G/A
Feb 14, 2022	venrock healthcare capital partners ii, l.p.	2.7%	1e+06	SC 13G/A

Recent SEC filings of Athira Pharma Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
Apr 16, 2024	3	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 09, 2024	ARS	ARS
Apr 09, 2024	DEF 14A	DEF 14A
Apr 09, 2024	DEFA14A	DEFA14A
Mar 28, 2024	PRE 14A	PRE 14A
Feb 22, 2024	S-8	Employee Benefits Plan
Feb 22, 2024	10-K	Annual Report

Peers (Alternatives to Athira Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Athira Pharma Inc News

Latest updates

Athira Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q1	2019Q4
Revenue	-	-	-	1,227,000	2,959,000	2,596,500	2,234,000	2,336,000	2,079,000	2,589,000	1,831,000	-	-	-
Costs and Expenses	6.3%	31,640,000	29,770,000	32,927,000	24,133,000	23,569,000	23,387,000	18,778,000	17,826,000	16,637,000	10,781,000	9,079,000	1,267,000	-
S&GA Expenses	18.3%	10,025,000	8,477,000	7,691,000	7,168,000	8,766,000	8,927,000	6,160,000	7,119,000	4,613,000	3,336,000	3,892,000	675,000	-
R&D Expenses	1.5%	21,615,000	21,293,000	15,236,000	16,965,000	14,803,000	14,460,000	12,618,000	10,707,000	12,024,000	7,445,000	5,187,000	592,000	-
Net Income	-6.4%	-29,597,000	-27,820,000	-30,135,000	-20,189,000	-24,335,000	-20,980,000	-16,339,000	-15,674,000	-13,974,000	-8,866,000	-7,702,000	-1,805,000	-
Net Income Margin	-5.1%	-20.88	-19.86	-18.53	-12.55	-9.81	-7.25	-6.21	-6.64	-7.68	-8.44	-	-	-
Free Cashflow	8.0%	-24,315,000	-26,435,000	-15,668,000	-21,884,000	-18,741,000	-17,317,000	-19,204,000	-10,427,000	-7,431,000	-7,609,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-16.7%	133	160	185	208	233	258	274	292	313	332	347	360	369	280	268	-	-	-	-
Current Assets	-16.9%	129	155	179	192	193	208	229	256	269	261	239	290	312	192	232	-	-	2.00	5.00
Cash Equivalents	-14.1%	78.00	91.00	110	114	105	96.00	87.00	95.00	118	111	107	132	128	61.00	166	-	-	2.00	3.00
Net PPE	-7.2%	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	1.00	-	-	-	-
Liabilities	-11.1%	27.00	30.00	30.00	23.00	22.00	23.00	12.00	11.00	11.00	11.00	11.00	9.00	6.00	5.00	8.00	7.00	6.00	5.00	3.00
Current Liabilities	-11.2%	26.00	29.00	29.00	22.00	20.00	21.00	10.00	10.00	9.00	9.00	9.00	8.00	4.00	4.00	8.00	-	-	1.00	1.00
Shareholder's Equity	-18.0%	107	130	155	185	211	235	262	281	302	321	336	351	363	274	259	-	-	-	-
Retained Earnings	-8.5%	-335	-309	-281	-248	-219	-191	-161	-141	-116	-95.89	-79.56	-63.88	-49.91	-41.04	-33.34	-	-	-21.09	-15.93
Additional Paid-In Capital	0.6%	442	440	437	435	432	429	426	424	420	417	416	415	413	315	293	-	-	1.00	1.00
Shares Outstanding	0.4%	38.00	38.00	38.00	38.00	38.00	38.00	38.00	38.00	38.00	37.00	37.00	36.00	36.00	-	-	-	-	-	-
Float	-	-	-	-	96.00	-	-	-	99.00	-	-	-	328	-	-	461	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	1.9%	-25,804	-26,293	-23,984	-24,282	-26,194	-15,667	-21,640	-18,590	-16,572	-18,177	-10,299	-7,317	-7,305	-10,665	-9,411	-2,862	-1,175	-	-	-
Share Based Compensation	20.2%	2,679	2,228	2,494	3,119	2,782	2,360	2,420	3,095	2,731	1,435	1,105	1,109	974	415	111	49.00	58.00	-	-	-
Cashflow From Investing	104.1%	13,041	6,391	20,690	32,486	35,522	24,647	13,632	-4,461	23,846	21,373	-14,199	11,455	-22,708	-115,758	-94,313	2.00	1.00	-	-	-
Cashflow From Financing	-100.0%	-	152	-	242	99.00	147	-	297	210	13.00	125	-260	97,211	21,323	184,283	85,304	1,840	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ATHA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 21,236	$ 21,293
General and administrative	6,451	8,477
Total operating expenses	27,687	29,770
Loss from operations	(27,687)	(29,770)
Grant income		157
Other income, net	1,350	1,793
Net loss	(26,337)	(27,820)
Unrealized gain on available-for-sale securities	212	927
Comprehensive loss attributable to common stockholders	$ (26,125)	$ (26,893)
Net loss per share attributable to common stockholders, basic	$ (0.69)	$ (0.73)
Net loss per share attributable to common stockholders, diluted	$ (0.69)	$ (0.73)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	38,321,573	37,923,402
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	38,321,573	37,923,402

ATHA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 77,821	$ 90,584
Short-term investments	44,267	56,835
Prepaid expenses and other current assets	4,920	5,682
Insurance recovery receivable related to legal settlement (Note 7)	1,628	1,628
Total current assets	128,636	154,729
Restricted cash	631	631
Property and equipment, net	3,144	3,388
Operating lease right-of-use asset	992	1,049
Other long-term assets	55	448
Total assets	133,458	160,245
Current liabilities:
Accounts payable	681	129
Accrued liabilities	14,537	18,343
Accrued legal settlement	10,000	10,000
Current operating lease liability	380	368
Total current liabilities	25,598	28,840
Operating lease liability, less current portion	1,118	1,217
Total liabilities	26,716	30,057
Stockholders' equity:
Common stock, $0.0001 par value; 900,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 38,326,652 and 38,172,603 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	442,418	439,739
Accumulated other comprehensive loss	(137)	(349)
Accumulated deficit	(335,543)	(309,206)
Total stockholders' equity	106,742	130,188
Total liabilities and stockholders' equity	$ 133,458	$ 160,245

About Athira Pharma Inc

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

CEO	Dr. Mark J. Litton M.B.A., MBA, Ph.D.
WEBSITE	athira.com
INDUSTRY	Biotechnology
EMPLOYEES	63

Athira Pharma Inc Frequently Asked Questions

What is the ticker symbol for Athira Pharma Inc? What does ATHA stand for in stocks?

ATHA is the stock ticker symbol of Athira Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Athira Pharma Inc (ATHA)?

As of Thu May 16 2024, market cap of Athira Pharma Inc is 103.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATHA stock?

You can check ATHA's fair value in chart for subscribers.

What is the fair value of ATHA stock?

You can check ATHA's fair value in chart for subscribers. The fair value of Athira Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Athira Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATHA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Athira Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether ATHA is over valued or under valued. Whether Athira Pharma Inc is cheap or expensive depends on the assumptions which impact Athira Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATHA.

What is Athira Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, ATHA's PE ratio (Price to Earnings) is -0.89 and Price to Sales (PS) ratio is 16.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATHA PE ratio will change depending on the future growth rate expectations of investors.